Article: | MedLuna.com

Overview

Journal Tunis Med

Specialty General Medicine

Date 2024 Jun 12

PMID 38864197

Authors

Dorra Jabr

Roua Hsasna

Salma Kefi

Rachid Kharrat

Hend Ben Neji

Raihane Ben Lakhal

Affiliations

Soon will be listed here.

Abstract

Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially fatal hematological disorder that requires urgent treatment. Once the diagnosis has been made, plasma exchange (PE) must be started immediately and until a response is obtained.

Aim: Evaluate PE in terms of responses and complications in the treatment of TTP.

Methods: This was a monocentric, descriptive, retrospective study including patients in whom TTP was diagnosed and treated with plasmapheresis in the clinical hematology department at Aziza Othmana Hospital, between January 2010 and December 2020.

Results: Our study included 26 patients. PE was initiated within a median of 1 day. The rhythm of exchanges was daily in 22 patients. Twenty PE-related complications were noted, hypocalcemia being the most frequent (30%). CR was achieved in 15 patients after PE alone. Nine patients were refractory, and six received 2nd-line treatment, with CR achieved in five patients. Relapse was noted in six patients (40%). They were treated by PE and only one patient received rituximab. Four patients had a response. The overall response rate was 69% and overall mortality was 30%. OS at 2 years was 68,3% and RFS was 84,4%. Factors associated with the achievement of CR were the fall in LDH at D5 of treatment (p=0,027,OR=0,59 ;IC 95%[0,32-1,08]) and the daily rhythm of PE (p=0,005, OR=0,35; IC 95%[0,14-0,91]).

Conclusion: Our results were comparable to those of the literature, but the rate of refractory disease was higher. Rituximab may enhance our results.

References

Willis M, Bandarenko N . Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease?. Semin Thromb Hemost. 2006; 31(6):700-8. DOI: 10.1055/s-2005-925476. View

Winters J . Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP). Hematology Am Soc Hematol Educ Program. 2017; 2017(1):632-638. PMC: 6142547. DOI: 10.1182/asheducation-2017.1.632. View

Elliott M, Heit J, Pruthi R, Gastineau D, Winters J, Hook C . Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol. 2009; 83(4):365-72. DOI: 10.1111/j.1600-0609.2009.01292.x. View

Deroux A, Sirodot M, Daguindau N, Barro C, Coppo P, Bouillet L . [Management of thrombotic thrombocytopenic purpura in two French centers: A series of 27 patients]. Rev Med Interne. 2015; 37(1):13-8. DOI: 10.1016/j.revmed.2015.05.003. View

Shemin D, Briggs D, Greenan M . Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007; 22(5):270-6. DOI: 10.1002/jca.20143. View

Sarode R, Bandarenko N, Brecher M, Kiss J, Marques M, Szczepiorkowski Z . Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher. 2013; 29(3):148-67. DOI: 10.1002/jca.21302. View

George J . How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010; 116(20):4060-9. DOI: 10.1182/blood-2010-07-271445. View

Blitzer J, Granfortuna J, GOTTLIEB A, Smith J, Theodorakis M, Zamkoff K . Thrombotic thrombocytopenic purpura: treatment with plasmapheresis. Am J Hematol. 1987; 24(4):329-39. DOI: 10.1002/ajh.2830240402. View

Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle P, Brenner B . von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339(22):1578-84. DOI: 10.1056/NEJM199811263392202. View

10.

Mariotte E, Azoulay E, Galicier L, Rondeau E, Zouiti F, Boisseau P . Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016; 3(5):e237-45. DOI: 10.1016/S2352-3026(16)30018-7. View

11.

Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S . Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008; 142(5):819-26. DOI: 10.1111/j.1365-2141.2008.07276.x. View

12.

Bauer P, Ostermann M, Russell L, Robba C, David S, Ferreyro B . Plasma exchange in the intensive care unit: a narrative review. Intensive Care Med. 2022; 48(10):1382-1396. PMC: 9372988. DOI: 10.1007/s00134-022-06793-z. View

13.

Onundarson P, Rowe J, Heal J, Francis C . Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution. Arch Intern Med. 1992; 152(4):791-6. View

14.

Lara Jr P, Coe T, Zhou H, Fernando L, Holland P, Wun T . Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Am J Med. 2000; 107(6):573-9. DOI: 10.1016/s0002-9343(99)00286-7. View

15.

Shumak K, Rock G, Nair R . Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med. 1995; 122(8):569-72. DOI: 10.7326/0003-4819-122-8-199504150-00002. View

16.

Wyllie B, Garg A, Macnab J, Rock G, Clark W . Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. Br J Haematol. 2006; 132(2):204-9. DOI: 10.1111/j.1365-2141.2005.05857.x. View

17.

Kremer Hovinga J, Vesely S, Terrell D, Lammle B, George J . Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2009; 115(8):1500-11. DOI: 10.1182/blood-2009-09-243790. View

18.

Kessler C, Khan B, Lai-Miller K . Thrombotic thrombocytopenic purpura: a hematological emergency. J Emerg Med. 2012; 43(3):538-44. DOI: 10.1016/j.jemermed.2012.01.027. View

19.

Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S . Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007; 136(3):451-61. DOI: 10.1111/j.1365-2141.2006.06448.x. View

20.

Bandarenko N, Brecher M . United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher. 1998; 13(3):133-41. DOI: 10.1002/(sici)1098-1101(1998)13:3<133::aid-jca7>3.0.co;2-z. View